EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

The European Medicines Agency authorised Yesintek, a biosimilar of ustekinumab, for use in psoriasis, psoriatic arthritis, and Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• YESINTEK (USTEKINUMAB)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Crohn Disease. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 13/02/2026